Research programme: multiple sclerosis therapies - Probiodrug/Synt:emAlternative Names: Syn-5001
Latest Information Update: 09 Mar 2011
At a glance
- Originator Probiodrug; Synt:em
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 11 Jul 2003 Preclinical trials in Multiple sclerosis in France (unspecified route)